Rakuten Medical is proud to announce an exclusive licensing agreement in the MENA region with Hikma Pharmaceuticals for pharmaceuticals and medical devices developed on our proprietary #Alluminox™ platform. This will further accelerate global reach of our innovative cancer treatment technology. https://lnkd.in/giqhwYTz
Rakuten Medical
Biotechnology
San Diego, California 8,053 followers
Rakuten Medical, Inc. is a global biotechnology company in pursuit of conquering cancer.
About us
Rakuten Medical, Inc. is a global biotechnology company developing and commercializing precision, cell-targeting investigational therapies on its AlluminoxTM platform, which, in pre-clinical studies have been shown to induce rapid and selective cell killing and tumor necrosis. Outside of Japan, Alluminox therapies have not yet been approved as safe or effective by any regulatory authority. The company’s first drug developed on the Alluminox platform, ASP-1929, has received approval from the Japanese Ministry of Health, Labour, and Welfare, and is currently the subject of a global phase 3 clinical trial for recurrent head and neck cancer. Rakuten Medical is committed to its mission to conquer cancer by delivering our innovative treatments as quickly and safely as possible to as many patients all over the world as possible. The company has locations in 6 countries, including the United States, where it is headquartered, Japan, Taiwan, the Netherlands, Switzerland and India. For more information, visit www.rakuten-med.com.
- Website
-
http://www.rakuten-med.com
External link for Rakuten Medical
- Industry
- Biotechnology
- Company size
- 201-500 employees
- Headquarters
- San Diego, California
- Type
- Privately Held
- Founded
- 2010
- Specialties
- Biotechnology, Cancer Therapeutics, and Clinical Research
Locations
Employees at Rakuten Medical
Updates
-
-
Rakuten Medical’s Co-CEO Mickey Mikitani and its transformative treatment technology #Alluminox™ platform is featured in ASCO Daily News. Mickey will be giving a keynote presentation about how we have been advancing the photoimmunotherapy-based technology with entrepreneurship at the 2023 ASCO Breakthrough on Aug 3 in Yokohama. https://lnkd.in/gaZG2gRp #ASCOBT23 #ASCO #HeadandNeckCancer #OralCancer #oralcancerawareness
Flash of Hope: Keynote Speaker Will Focus on Power of Innovation in Photoimmunotherapy for Future Oncology Care
dailynews.ascopubs.org
-
Attending #BIOAsiaTaiwan2023? Rakuten Medical Louise Chang will present at BIO Asia Taiwan in Taipei. Stop by Room 402A, 4F, TaiNEX at 9:45 AM, July 27 to learn more about our investigational #Alluminox™ platform. On-demand presentation is also available.
-
-
Join us on August 10th at 8:30am PT / 11:30am ET for Rakuten Medical’s virtual R&D Day, featuring Ann Gillenwater (MD Anderson Cancer Center), discussing the preliminary safety and efficacy findings from its open-label Phase 1b/2 study of photoimmunotherapy-based Alluminox™ treatment using ASP-1929 in combination with anti-PD-1 therapy in recurrent or metastatic head and neck squamous cell carcinoma (#HNSCC). Register here: https://lnkd.in/gAe_mbaW Learn more at our press release: https://lnkd.in/gwtjR6Hc
-
-
The preliminary results of Rakuten Medical's ASP-1929-181 study (ASP-1929 Alluminox treatment + PD-1 combo) have been just presented by Dr. Ann Gillenwater at #AHNS2023. The promising data includes overall survival (OS) rate at 18 months of 53.5% (95% CI 18.5‒79.3) at data cutoff. Read more about the findings in our press release at https://lnkd.in/gdusJnWN
-
-
Attending #AHNS2023? Come meet us at Rakuten Medical booth to learn more about our investigational photoimmunotherapy-based Alluminox™ platform.
-
-
Rakuten Medical is excited to share that Dr. Ann Gillenwater will be presenting safety and efficacy data from a Phase 1b/2 study of Alluminox treatment (photoimmunotherapy) using ASP-1929 in combination with anti-PD-1 therapy in recurrent or metastatic head and neck squamous cell carcinoma at #AHNS2023.
-
-
Our Co-CEO Takashi Toraishi was interviewed by Worldfolio on how Rakuten Medical aims to advance cancer treatment through Alluminox™ platform. Read the full interview here: https://lnkd.in/gUFrdD8z
Rakuten Medical: Advancing Oncology
theworldfolio.com
-
🎉 Exciting news! We're thrilled to have Medlight SA, a Rakuten Medical Company as a Gold Sponsor for #ipa2023 Congress! Their invaluable support is driving advancements in photodynamic therapy and diagnostics. Thank you for being part of this incredible event! #Medlight #photodynamictherapy #diagnostics
-
-
Medlight SA, a Rakuten Medical Company will be sponsoring #IPA2023, which is only a few days away! Please stop by the Medlight SA, a Rakuten Medical Company booth to hear about our latest developments. Through 25+ years of experience in the light dosimetry field, Medlight SA, a Rakuten Medical Company has been complying with the highest regulatory standards with a proven track record of ISO certification audits without any major non-conformities. https://www.medlight.com/
Home
https://www.medlight.com